Herbs (Global Traditional) · Southeast Asian
Kaempferia galanga
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Kaempferia galanga contains ethyl p-methoxycinnamate (EMC) as its primary bioactive compound. It reduces inflammation by inhibiting cyclooxygenase-2 (COX-2) and nuclear factor-kappa B (NF-κB) pathways.
Kaempferia galanga L., commonly known as galangal or kencur, is a perennial herbaceous plant in the Zingiberaceae family native to Southeast Asia, including Indonesia, Malaysia, and Thailand. The rhizomes serve as the primary medicinal source and are typically extracted using ethanol, acetone, or essential oil distillation methods to yield bioactive fractions rich in flavonoids, phenols, and phenylpropanoids.
Human clinical evidence is extremely limited with only two small trials identified: one RCT (n=16) testing topical extract for aphthous stomatitis and another comparing 160mg/day oral extract to meloxicam for knee osteoarthritis over 10 days (no PMIDs available). No meta-analyses or large-scale RCTs exist; most evidence comes from preclinical studies in rodent models of inflammation, colitis, and viral infection.
Clinical studies used 160mg/day of oral extract for 10 days in osteoarthritis. Animal studies suggest 300mg/kg body weight as optimal for anti-inflammatory effects. No standardization details for active compounds are specified in human trials. Consult a healthcare provider before starting any new supplement.
Kaempferia galanga (kencur/aromatic ginger) rhizome is used primarily as a spice and traditional medicine rather than a significant macronutrient source. Typical fresh rhizome composition per 100g: water ~70–75g, carbohydrates ~15–20g, protein ~2–3g, fat ~0.5–1.5g, dietary fiber ~3–5g, ash ~3–5g, with modest amounts of potassium (~200–350mg), calcium (~30–50mg), phosphorus (~40–60mg), iron (~2–4mg), and trace amounts of zinc and manganese. Vitamin content is low, with small amounts of vitamin C (~5–10mg/100g fresh) and negligible B-vitamins. The primary pharmacological and nutritional value lies in its bioactive volatile and non-volatile compounds. The essential oil (2–4% of dry weight) is dominated by ethyl p-methoxycinnamate (EPMC, typically 30–70% of essential oil, ~0.6–2.8% of dry rhizome weight), which is the principal bioactive constituent responsible for anti-inflammatory, analgesic, and cytotoxic activities. Other notable essential oil constituents include ethyl cinnamate (~5–15% of oil), borneol (~5–10%), camphene (~3–8%), δ-3-carene, p-methoxystyrene, and cineole. Non-volatile bioactive compounds include kaempferol (a flavonol, ~0.1–0.5% dry weight), kaempferide (4'-methyl ether of kaempferol), apigenin and its derivatives, luteolin, and various phenolic acids including p-methoxycinnamic acid and caffeic acid. Total phenolic content ranges approximately 15–45 mg gallic acid equivalents (GAE)/g dry extract depending on extraction method, contributing to moderate antioxidant capacity (DPPH IC50 values typically 50–200 µg/mL for ethanolic extracts). The rhizome also contains starch granules and small amounts of saponins and alkaloids. Bioavailability notes: EPMC demonstrates reasonable oral bioavailability in animal models due to its lipophilic nature (log P ~2.2), and its anti-inflammatory effects have been observed at oral doses of 160mg standardized extract/day in humans. Kaempferol has relatively low oral bioavailability (~2–5%) due to extensive first-pass metabolism and glucuronidation, though co-consumption with dietary fats or piperine may modestly enhance absorption. The essential oil components are readily absorbed through mucosal surfaces, supporting topical efficacy for oral ulcer applications.
Ethyl p-methoxycinnamate (EMC) in Kaempferia galanga inhibits COX-2 enzyme activity, reducing prostaglandin E2 production. It also suppresses NF-κB activation, decreasing inflammatory cytokine release including TNF-α and IL-1β. These dual pathways contribute to its anti-inflammatory and analgesic effects.
One randomized controlled trial demonstrated that 160mg daily of Kaempferia galanga extract provided pain relief equivalent to meloxicam in knee osteoarthritis patients. A small RCT (n=16) showed topical application significantly reduced oral ulcer size and pain scores compared to placebo. Evidence remains limited due to few studies and small sample sizes, requiring larger clinical trials for definitive efficacy confirmation.
Kaempferia galanga appears well-tolerated in clinical studies with no serious adverse effects reported. Potential interactions with anticoagulant medications may occur due to anti-inflammatory properties. Safety during pregnancy and breastfeeding has not been established. Individuals with bleeding disorders should consult healthcare providers before use.
